Sanofi

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, February 26, 2024
NSCLC, Acquisition, Research, Neoplasm, Investment, Melanoma, Conference, RAS, Lung cancer, Safety, Sanofi, GAAP, PDAC, Patient, Acceleration, Clinical trial, Congress, Trial of the century, Colorectal cancer, Pharmaceutical industry

“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.

Key Points: 
  • “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
  • Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
  • Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Retrieved on: 
Friday, February 23, 2024
AMF, File, Sanofi, Annual, Bank statement, Form

Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Key Points: 
  • Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
    Paris, February 23, 2024.
  • Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
  • These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-r...
    In addition, the Form 20-F is available on the website of the SEC ( www.sec.gov ) and the “Document d’Enregistrement Universel” is available on the website of the AMF ( www.amf-france.org ).
  • A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Senior, TPG Inc., Aidia, Teva, Integrated care, Business development, Sanofi, Chairperson, Therapy, Evaluation, Patient, Teva Pharmaceuticals, Compugen, Pharmaceutical industry

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Pharmaceutical, RSV, AstraZeneca, Immunization, FDA, SWOT, EU4, Nirsevimab, Sanofi, Infant, Ventricular septal defect, Disease, Research, Immune system, Pharmaceutical industry

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.

Crisp Raises $50M in Series B Extension as CPG Brands Rapidly Adopt a Collaborative Commerce Approach for Sales, Marketing and Supply Chain Management

Retrieved on: 
Thursday, February 22, 2024
Software, Supply Chain Management, Online Retail, Professional Services, Business, Fintech, Data Management, Technology, Retail, Other Professional Services, Finance, Consulting, Cloud, Acquisition, FirstMark Capital, Forecasting, Marketing, Growth, CPG, Kraft Heinz, Sanofi, Blue Cloud Ventures, Hormel Foods, Atlas

TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.

Key Points: 
  • TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.
  • Crisp previously raised a total of $60M in equity, bringing the total equity raised to $80M.
  • These insights enable brands and retailers to optimize the manufacturing, distribution, merchandising and marketing of CPG products through every retail channel.
  • We solve real problems and help CPG brands strengthen sales, marketing, and their relationships with retailers,” said Are Traasdahl, founder and CEO of Crisp.

ORI Capital Raises $260 Million for Second Life Sciences Fund

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, Asset Management, Professional Services, Fintech, Therapy, Cancer, AI, Investment, Synthetic biology, Growth, Vertex, Hope, IPO, Sanofi, RNA, Fund, Patient, Biology, Mortality, DSM-IV codes, Development, DNA, Environment, Pharmaceutical industry

ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.

Key Points: 
  • ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.
  • Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies.
  • ORI Capital is a pioneer in adopting a quantamental strategy in biotech venture investment combing data analysis with fundamental research.
  • ORI Healthcare Fund II will actively deploy capital in these new approaches to support truly innovative companies that can bring hope to patients in need globally.

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

Retrieved on: 
Thursday, March 7, 2024
OBE, GSK, Prostate cancer, Parexel, Conference, Human, Sanofi, Patient, MPH, Medicine, Pharmaceutical industry

NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England. Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.

Key Points: 
  • Patients as Partners® Europe announces its dates, keynotes and topics for the London meeting which is attended by pharma and biotech R&D, patient advocacy, and technologists to include and empower the patient voice for greater efficiencies in medicine development.
  • NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England.
  • Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.
  • "Patients as Partners® Europe presents case examples on how patient involvement in clinical research can accelerate medicine development, how it can improve better access, inclusivity and diversity," said Valerie Bowling, Executive Director
    "Patients as Partners Europe brings advocates and sponsors together in a unique forum focused on improving collaborations that result in meaningful impact for patients," said 2024 co-chair, Victoria DiBiaso, MPH, Global Head, Patient Informed Development & Health Value Translation, Sanofi.

70 companies unite to launch Tent UK, a new coalition of businesses committed to connecting refugees to work

Retrieved on: 
Tuesday, March 5, 2024
The Adecco Group, IHG Hotels & Resorts, Virginity, Compass Group, GSK, Education, Moody's Investors Service, Pret a Manger, Arcadis, Cooperative, Admiral Group, AA, Salesforce, Ageing, IKEA, DLA Piper, Bank, Health, Methodology, Linklaters, EBay, Dow Jones, Microsoft, Partnership, International, Woman, Ben & Jerry's, Thames Water, Cisco, Lineage Logistics, Accenture, Automation, Employment, Starbucks, Bank of America, Research, Bloomberg, Kraft Heinz, Visa, Government, Pret, Data, John Menzies, Foodservice, McDonald's, ISS, Ipsos, BP, Sanofi, HR, Citigroup, Piper, Biogen, Creative industries

LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.

Key Points: 
  • LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.
  • Tent is uniquely placed and ready to help companies develop ambitious programmes to include refugees."
  • "Tent is immensely proud to have brought together 70 leading businesses resolved to connect refugees to meaningful employment," said Jen Stobart, UK Director at Tent.
  • Tent UK is Tent's sixth national coalition to launch, adding to existing coalitions in Canada, France, Mexico, Spain and the United States.

Vaniam Group™ Hires Carol Scholz as Executive Vice President of Client Solutions

Retrieved on: 
Monday, March 4, 2024
J&J, AstraZeneca, Oncology, Marketing, GSK, Curio, Growth, Executive Committee, Sanofi, McKesson Corporation, Health, Science

CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions. In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™, Vaniam Group's industry leading platform for scientific exchange and insights gathering. She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.

Key Points: 
  • CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions.
  • In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™ , Vaniam Group's industry leading platform for scientific exchange and insights gathering.
  • She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.
  • "Carol brings a passion for delivering strategic solutions and operational excellence, always anchored in the science and centered around the needs of the patient," said Ms. Herzog.

StopAfib.org and Leading Experts Call for Renewed Efforts to Improve Atrial Fibrillation Patient Care During American Heart Month

Retrieved on: 
Wednesday, February 21, 2024
Black History Month, Woman, Education, Research, MD, Quality of life, Cardiology, Ventricular fibrillation, Stroke, American Heart Month, Geography, Arrhythmia, Health, Atrial fibrillation, Sanofi, Patient, Diagnosis, Health equity, Nursing

DALLAS, Feb. 21, 2024 /PRNewswire/ -- StopAfib.org, joined by a task force of experts representing the nation's leading cardiology and cardiothoracic surgery organizations, is calling for renewed efforts to address health disparities and improve care for people living with atrial fibrillation (also known as AF or afib), an irregular and sometimes rapid heartbeat that can cause life-threatening complications, including stroke and heart failure.1

Key Points: 
  • Task force outlines current health disparities and strategies to advance the patient experience across the continuum of care in newly issued call-to-action report.
  • Recognizing the need for more equitable care, StopAfib.org convened the task force to develop a new call-to-action report, "Addressing Health Equity to Improve Atrial Fibrillation Patient Experiences and Outcomes."
  • For patients with AF, timely and proper care is an essential component of long-term health.
  • The report also aims to empower patients to better understand their condition and play a more active role in their care."